ArticleNeurology open access2026
Association of Thromboelastography With Hematoma Expansion and Disability in Spontaneous Intracerebral Hemorrhage: A Multicenter Study.
Article in Neurology open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background and Objectives: Hematoma expansion (HE), an increase in bleeding into the brain, is a modifiable cause of disability and death after intracerebral hemorrhage (ICH). Some specialized hemostatic biomarkers are associated with HE. Widely available hemostatic biomarkers could improve our understanding of HE and lead to targeted treatments. Methods: We conducted a multicenter, prospective, cohort study of patients with spontaneous ICH between 2019 and 2023 at 6 medical centers across the United States. Patients with an initial CT scan within 12 hours of symptom onset were enrolled. All patients had initial and follow-up CT scans for HE calculation and a blood draw that occurred before follow-up imaging. Patients who received desmopressin were excluded from analysis. Correlation between continuous numerical variables (i.e., HE and hemostatic biomarkers) was calculated with Spearman correlation. Correlations between the 3-month modified Rankin Scale (mRS) and biomarkers were calculated using Kendall correlation. Results: We enrolled 82 patients with spontaneous ICH (34.1% women) with a mean age of 61 ± 13.3 years. Symptom onset occurred within a median time of 1.8 (1.15-4.48) hours before first CT scan imaging and 5.8 (4.45-7.57) hours before blood draw. Seventeen (21%) used aspirin, 4 (5%) used clopidogrel, and none used anticoagulants before ICH. The Thromboelastography (TEG) Coagulation Index, a composite calculation from individual parameters, was correlated with subsequent HE ( Discussion: Hemostatic biomarkers from TEG, particularly those related to clot strength and fibrin generation, were associated with subsequent HE and the mRS at 3 months. These results suggest that hemostatic biomarkers have potential to predict HE and functional outcomes in a broad swath of patients with spontaneous ICH.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.